Prognostic, Predictive, and POC: Biomarkers from Research to Clinic

This conference brings together researchers from academic institutions and industry to discuss the utilization/deployment of biomarkers in research settings, the clinic, and point-of-care (POC) setting.

Agenda Topics:
- Cardiovascular and Metabolic Diseases
- Developing Diagnostics and Therapeutics in CNS Diseases using Biomarkers
- Examination of Prognostic versus Predictive Biomarkers
* Algorithms for Prediction and Response
* Commercial Impact and Clinical Adoption
* Current Examples in the Clinic and their Impact
* Disease Classes Addressed Currently
- Immunology Biomarkers and the Microbiome
- Oncology Biomarkers: Research to Clinical Trajectory
* Various Cancer Classes such as Breast Cancer, Colorectal Cancer, Lung Cancer, GI Cancers
- Point-of-Care Diagnostics and Mobile Point-of-Care (mPOC) Diagnostics
* Biomarkers
* Technologies for Deployment
- R&D Pipeline of Markers with Associated Therapeutics
- The Impact of Next-Generation Sequencing (NGS) on Biomarker Analysis
* Clinical Applications of RNA-Seq
- Various Classes of Biomarkers: Protein, Gene-Expression, microRNA, Epigenetic

+ show speakers and program
Keynote Speakers:
- Khusru Asadullah
Vice President/Head of Global Biomarkers, Bayer Healthcare Pharmaceuticals AG
- Mark Curran
VP Immunology Systems Pharmacology & Biomarkers, Janssen Pharmaceutical Research & Development/Johnson & Johnson
- Razelle Kurzrock
Director, Center for Personalized Cancer Therapy and Clinical Trials Office, Chief, Division of Hematology and Oncology, University of California-San Diego Moores Cancer Center
- Aydogan Ozcan
Chancellor's Professor, University of California Los Angeles

Other Confirmed Speakers:
- Stuart Lipton, Professor and Scientific Director, Sanford-Bunham Center for Neuroscience and Aging Research
- David Cheresh, Distinguished Professor of Pathology , University of California-San Diego
- Howard Federoff, EVP Health Sciences, Exec Dean, Professor of Neurology, Georgetown University Medical Center
- Shawn Baker, Chief Science Officer and Co-Founder, AllSeq Inc
- David Kallend, Vice President, Global Medical Director, The Medicines Company
- Christos Argyropoulos, Assistant Professor, Division of Nephrology, University of New Mexico
- Anand Giddabasappa, Principal Scientist, Global Science and Technology, Pfizer
- Scott Lippman, Associate Vice Chancellor for Cancer Research and Care, Moores Cancer Center & University of California-San Diego
- Terri McClanahan, Director, Profiling & Expression, Merck Biologics Discovery
- Denise Faustman, Director, Immunobiology Laboratory & Associate Professor of Medicine, Massachusetts General Hospital/Harvard Medical School
- Hugh Bruck, Professor, Department of Mechanical Engineering, University of Maryland
- George Zouridakis, Professor, Engineering Technology, Electrical & Computer Engineering, University of Houston
- William Mobley, Distinguished Professor and Chair, Department of Neurosciences, University of California-San Diego
- Donald Durden, Professor and Vice Chair for Research, Associate Director for Pediatric Oncology, University of California-San Diego Moores Cancer Center
- Serguei Kozlov, Leidos Biomedical Research, Inc. Principal Scientist, Center for Advancer Preclinical Research, NIH

15 Jan - 16 Jan 2015

San Diego
United States of America
meeting website